azd-2327
Small moleculeexperimental
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jan 1, 2009 (NCT00759395)
Timeline
2000s
- Jan 1, 2009
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Delta opioid receptorAGONIST
OPRD1 agonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- 4-((3-aminophenyl)(4-(4-fluorobenzyl)piperazin-1-yl)methyl)-n,n-diethylbenzamide
- azd2327
- azd2327
- azd2327
- azd 2327
- azd-2327
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00759395 | Phase 2 | Jan 1, 2009 | AstraZeneca, National Institute of Mental Health (NIMH) |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AstraZeneca | For profit | 1 | 1 | 1 | 2009 |
| National Institute of Mental Health (NIMH) | Government | 1 | 0 | 1 | 2009 |
2 organizations
Page 1 / 1